Insider Trading Alert - LCI, HCP And NVAX Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, June 18, 2014, 77 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $879.50 to $18,369,675.13.

Highlighted Stocks Traded by Insiders:

Lannett (LCI) - FREE Research Report

Bedrosian Arthur P, who is President and CEO at Lannett, sold 5,000 shares at $46.96 on June 18, 2014. Following this transaction, the President and CEO owned 649,851 shares meaning that the stake was reduced by 0.76% with the 5,000-share transaction.

Farber David, who is 10% Owner at Lannett, sold 10,000 shares at $43.52 on June 18, 2014. Following this transaction, the 10% Owner owned 77,500 shares meaning that the stake was reduced by 11.43% with the 10,000-share transaction.

Taveira Paul, who is Director at Lannett, sold 1,000 shares at $46.94 on June 18, 2014. Following this transaction, the Director owned 15,625 shares meaning that the stake was reduced by 6.02% with the 1,000-share transaction.

The shares most recently traded at $46.97, up $0.03, or 0.06% since the insider transaction. Historical insider transactions for Lannett go as follows:

  • 4-Week # shares bought: 500
  • 4-Week # shares sold: 10,000
  • 12-Week # shares bought: 500
  • 12-Week # shares sold: 10,000
  • 24-Week # shares bought: 500
  • 24-Week # shares sold: 10,000

The average volume for Lannett has been 667,000 shares per day over the past 30 days. Lannett has a market cap of $1.7 billion and is part of the health care sector and drugs industry. Shares are up 42.81% year-to-date as of the close of trading on Wednesday.

Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of branded pharmaceutical products in the United States. It offers solid oral, extended release, topical, and oral solution finished dosage forms of drugs that address a range of therapeutic areas. The company has a P/E ratio of 43.3. Currently, there are 4 analysts who rate Lannett a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on LCI - FREE

TheStreet Quant Ratings rates Lannett as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Lannett Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

HCP (HCP) - FREE Research Report

Klaritch Thomas, who is Executive Vice President at HCP, sold 40,000 shares at $41.29 on June 18, 2014. Following this transaction, the Executive Vice President owned 202,565 shares meaning that the stake was reduced by 16.49% with the 40,000-share transaction.

The shares most recently traded at $40.84, down $0.45, or 1.1% since the insider transaction. Historical insider transactions for HCP go as follows:

  • 4-Week # shares sold: 10,114
  • 12-Week # shares sold: 30,869
  • 24-Week # shares sold: 30,869

The average volume for HCP has been 2.6 million shares per day over the past 30 days. HCP has a market cap of $18.5 billion and is part of the financial sector and real estate industry. Shares are up 11.92% year-to-date as of the close of trading on Wednesday.

HCP, Inc. is an independent hybrid real estate investment trust. The fund invests in real estate markets of the United States. The stock currently has a dividend yield of 5.39%. The company has a P/E ratio of 20.5. Currently, there are 3 analysts who rate HCP a buy, 2 analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HCP - FREE

TheStreet Quant Ratings rates HCP as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, expanding profit margins, good cash flow from operations and notable return on equity. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full HCP Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Novavax (NVAX) - FREE Research Report

Trizzino John, who is SVP, Commercial Operations at Novavax, bought 5,500 shares at $4.51 on June 18, 2014. Following this transaction, the SVP, Commercial Operations owned 22,000 shares meaning that the stake was boosted by 33.33% with the 5,500-share transaction.

The shares most recently traded at $4.72, up $0.21, or 4.47% since the insider transaction. Historical insider transactions for Novavax go as follows:

  • 4-Week # shares bought: 75,000
  • 4-Week # shares sold: 29,000
  • 12-Week # shares bought: 75,000
  • 12-Week # shares sold: 29,000
  • 24-Week # shares bought: 115,154
  • 24-Week # shares sold: 29,000

The average volume for Novavax has been 4.6 million shares per day over the past 30 days. Novavax has a market cap of $1.1 billion and is part of the health care sector and drugs industry. Shares are down 8.59% year-to-date as of the close of trading on Wednesday.

Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing recombinant protein nanoparticle vaccines and adjuvants. Currently, there are 3 analysts who rate Novavax a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NVAX - FREE

TheStreet Quant Ratings rates Novavax as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and weak operating cash flow. Get the full Novavax Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Stocks Tumble as Dow Heads for Eighth Straight Drop

Stocks Tumble as Dow Heads for Eighth Straight Drop

Video: Here's Why One Markets Pro Is Raising Cash Right Now

Video: Here's Why One Markets Pro Is Raising Cash Right Now

Mesoblast Soars on Stem-Cell Treatment Data

Mesoblast Soars on Stem-Cell Treatment Data

Trade Tussle Sinks Stocks, Oil Slides, Micron, Daimler - 5 Things You Must Know

Trade Tussle Sinks Stocks, Oil Slides, Micron, Daimler - 5 Things You Must Know

Bank of England Holds Rates Steady, But Vote Shift Signals Hawkish Tone

Bank of England Holds Rates Steady, But Vote Shift Signals Hawkish Tone